头孢地尔对囊性纤维化患者伯克霍尔德菌复合体的体外活性
本研究评估头孢地尔对来自美国囊性纤维化患者的150株伯克霍尔德菌复合体(Bcc)和伯克霍尔德菌的体外活性,并与16种其他抗菌药物的历史药敏数据比较。头孢地尔MIC50为0.06 mg/L(ID-BMD)和0.03 mg/L(ID-AD),MIC90均为8 mg/L,对多数菌种MIC90较低,且不被PenA1水解。
要点
- 头孢地尔对Bcc和B. gladioli临床分离株具有广泛体外活性。
- 对B. multivorans和B. vietnamiensis的MIC90升高。
- 头孢地尔不被纯化的PenA1水解,且不诱导blaPen表达。
核心结论
- 头孢地尔对囊性纤维化患者的Bcc和B. gladioli分离株表现出广泛体外活性,并对关键β-内酰胺酶介导的耐药机制稳定。
研究设计与样本
- 研究纳入150株代表多个Bcc菌种和B. gladioli的临床分离株,采用铁缺乏肉汤微量稀释法(ID-BMD)和铁缺乏琼脂稀释法(ID-AD)测定头孢地尔MIC。
主要发现
- 头孢地尔MIC50和MIC90分别为0.06和8 mg/L(ID-BMD)以及0.03和8 mg/L(ID-AD)。
- B. cenocepacia、B. cepacia、B. gladioli和多数其他Bcc菌种的MIC90较低,而B. multivorans和B. vietnamiensis的MIC90升高。
- 与16种其他药物的历史数据相比,头孢地尔MIC50最低;头孢地尔不诱导blaPen表达,且不被纯化的PenA1水解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Burkholderia cepacia complex (Bcc) and Burkholderia gladioli are intrinsically multidrug-resistant pathogens that cause chronic pulmonary infections in individuals with cystic fibrosis (CF) and severe infections in other vulnerable populations. Therapeutic options remain limited as resistance to commonly used agents continues to emerge. OBJECTIVES: To evaluate the in vitro activity of cefiderocol against a collection of Bcc and B. gladioli isolates from individuals with CF in the USA and to compare these findings with historical susceptibility data for 16 other antimicrobial agents. METHODS: A total of 150 clinical isolates representing multiple Bcc species and B. gladioli were tested. Cefiderocol MICs were determined using iron-depleted broth microdilution (ID-BMD) and iron-depleted agar dilution (ID-AD). Species-specific MIC distributions were assessed, and cefiderocol activity was compared with historical MIC data for 16 other antimicrobial agents previously tested against the same isolate panel. Mechanistic studies evaluated blaPenA expression and hydrolysis of cefiderocol by purified PenA1. RESULTS: Cefiderocol MIC50 and MIC90 values were 0.06 and 8 mg/L, and 0.03 and 8 mg/L, respectively, by both ID-BMD and ID-AD. Low MIC90 values were observed for Burkholderia cenocepacia, B. cepacia, B. gladioli, and most 'other Bcc' species, whereas elevated MIC90 values were detected for Burkholderia multivorans and Burkholderia vietnamiensis. Cefiderocol demonstrated the lowest MIC50 values when compared with historical data for 16 other agents; did not induce blaPen expression; and was not hydrolysed by purified PenA1. CONCLUSIONS: Cefiderocol demonstrated broad in vitro activity against Bcc and B. gladioli isolates from individuals with CF and showed stability against key β-lactamase-mediated resistance mechanisms.
引用
- Mojica, Zeiser, Becka, et al. In vitro activity of cefiderocol against Burkholderia cepacia complex and Burkholderia gladioli clinical isolates from cystic fibrosis patients in the United States. J Antimicrob Chemother. 2026. PMID: 42944775. doi:10.1093/jac/dkag347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。